Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
Sandisk shares rise on Nasdaq-100 inclusion
08:05am, Monday, 13'th Apr 2026
Sandisk (NASDAQ:SNDK) shares rose about 6% to about $905 on the news that the company will be added to the Nasdaq-100 Index prior to the market open on...
NanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMI
10:45am, Saturday, 11'th Apr 2026
NanoViricides (NYSE-A:NNVC) CEO Dr. Anil Diwan talked with Proactive about the company's recent FDA application for rare pediatric disease designation for its antiviral candidate NV-387, highlighting
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI
06:22am, Saturday, 11'th Apr 2026
NanoViricides (NYSE-A:NNVC) CEO Dr. Anil Diwan talked with Proactive about the company’s recent FDA application for rare pediatric disease designation for...
Anthropic pulls ahead of OpenAI as revenue race heats up
11:37am, Tuesday, 07'th Apr 2026
Anthropic, the artificial intelligence company backed by Google, Amazon, and Microsoft, has crossed $30 billion in annualized revenue, outpacing OpenAI for...
NanoViricides seeks rare pediatric disease status for measles drug NV-387
09:35am, Tuesday, 07'th Apr 2026
NanoViricides (NYSE-A:NNVC) said on Tuesday it has filed an application with the US Food and Drug Administration for Rare Pediatric Disease Drug designation for its antiviral candidate NV-387 as a tre
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of
NanoViricides to begin Phase II trial of MPox treatment in Congo
09:43am, Wednesday, 01'st Apr 2026
NanoViricides (NYSE-A:NNVC) said on Wednesday it expects to begin a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of mpox in the Democratic Republic of Congo (DRC) shortl
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
08:30am, Wednesday, 01'st Apr 2026
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to
NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial
09:54am, Wednesday, 11'th Mar 2026
NanoViricides (NYSE-A:NNVC) said on Wednesday it has completed manufacturing of its NV-387 oral drug product, clearing a key step toward dosing patients in an upcoming clinical trial for mpox. The cli
SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot
NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI
11:06am, Saturday, 21'st Feb 2026
NanoViricides (NYSE-A:NNVC) earlier this week provided an update on the advancement of its broad-spectrum antiviral candidate NV-387, outlining progress in Mpox clinical development and confirming orp
NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI
06:00am, Saturday, 21'st Feb 2026
NanoViricides (NYSE-A:NNVC) earlier this week provided an update on the advancement of its broad-spectrum antiviral candidate NV-387, outlining progress in...
NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study
11:29am, Thursday, 19'th Feb 2026
NanoViricides has provided an update on the development of its investigational antiviral NV-387, alongside the filing of its quarterly report for the fiscal quarter ending December 31, 2025. NanoViric
NanoViricides seeks FDA orphan status for MPox drug
09:28am, Thursday, 12'th Feb 2026
NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antiviral therapies, has filed for Orphan Drug Designation (ODD) with the US Food and Drug Administration
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
08:30am, Thursday, 12'th Feb 2026
SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the de
